Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)
Gilead Sciences' (GILD) quarterly Income from Non-Controlling Interests came in at -$12.0 million in Q4 2023, down 71.43% on a YoY basis from -$42.0 million in Q4 2022, and down 50.0% quarter-over-quarter from -$8.0 million in Q3 2023.
Analysis
Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends
Gilead Sciences (GILD) has reported Income from Non-Controlling Interests for 15 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Income from Non-Controlling Interests fell 71.43% year-over-year to -$12.0 million; the trailing twelve-month figure through Sep 2024 stood at -$12.0 million (up 74.47% YoY), and the FY2023 full-year result was -$52.0 million, down 100.0% from the prior year.
- Income from Non-Controlling Interests slipped to -$12.0 million in Q4 2023 per GILD's latest filing, from -$8.0 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$3.0 million in Q3 2019 and bottomed at -$26.0 million in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged -$7.9 million across 5 years, with a median of -$7.0 million in 2019.
- The sharpest annual moves came in 2019 and 2022: Income from Non-Controlling Interests sank 800.0% in 2019, then surged 50.0% in 2022.
- Over 5 years, Income from Non-Controlling Interests stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then gained by 14.29% to -$6.0 million in 2021, then decreased by 16.67% to -$7.0 million in 2022, then tumbled by 71.43% to -$12.0 million in 2023.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$12.0 million, -$8.0 million, and -$6.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -100.77 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | -8.00 Mn |
| Jun 30, 2023 | -6.00 Mn |
| Mar 31, 2023 | -26.00 Mn |
| Dec 31, 2022 | -7.00 Mn |
| Sep 30, 2022 | -3.00 Mn |
| Jun 30, 2022 | -9.00 Mn |
| Mar 31, 2022 | -7.00 Mn |
| Dec 31, 2021 | -6.00 Mn |
| Sep 30, 2021 | -6.00 Mn |
| Jun 30, 2021 | -5.00 Mn |
| Mar 31, 2021 | -7.00 Mn |
| Dec 31, 2020 | -7.00 Mn |
| Sep 30, 2020 | -7.00 Mn |
| Jun 30, 2020 | -7.00 Mn |
| Mar 31, 2020 | -13.00 Mn |
| Dec 31, 2019 | -7.00 Mn |
| Sep 30, 2019 | -3.00 Mn |
| Jun 30, 2019 | -5.00 Mn |
| Mar 31, 2019 | -7.00 Mn |